XML 31 R24.htm IDEA: XBRL DOCUMENT v3.3.0.814
Collaboration and Other Agreements, Les Laboratoires Servier (Details)
 1 Months Ended 3 Months Ended 9 Months Ended
Sep. 30, 2012
USD ($)
Nov. 30, 2011
USD ($)
Sep. 30, 2015
USD ($)
Sep. 30, 2014
USD ($)
Sep. 30, 2015
USD ($)
Molecule
Sep. 30, 2014
USD ($)
Dec. 31, 2014
USD ($)
Collaboration And Other Agreements [Line Items]              
Deferred revenue included in current liabilities     $ 7,163,000   $ 7,163,000   $ 14,248,000
Deferred revenue included in long-term liabilities     11,889,000   $ 11,889,000   16,472,000
Servier [Member] | Servier MGA271 [Member]              
Collaboration And Other Agreements [Line Items]              
Agreement beginning date         November 2011    
Non-refundable upfront payment   $ 20,000,000          
Additional Potential License Fees Under Agreement     30,000,000   $ 30,000,000    
Additional Potential Clinical Milestone Payments Under Agreement     47,000,000   47,000,000    
Additional Potential Regulatory Milestone Payments Under Agreement     140,000,000   140,000,000    
Additional Potential Sales Milestone Payments Under Agreement     208,000,000   $ 208,000,000    
Original period of development         27 months    
Expected period of development         42 months    
Recognized revenue under agreement     14,000 $ 200,000 $ 100,000 $ 600,000  
Deferred revenue             100,000
Servier [Member] | Servier DART [Member]              
Collaboration And Other Agreements [Line Items]              
Agreement beginning date         September 2012    
Non-refundable upfront payment $ 20,000,000            
Additional Potential License Fees Under Agreement     65,000,000   $ 65,000,000    
Additional Potential Clinical Milestone Payments Under Agreement     98,000,000   98,000,000    
Additional Potential Regulatory Milestone Payments Under Agreement     300,000,000   300,000,000    
Additional Potential Sales Milestone Payments Under Agreement     630,000,000   $ 630,000,000    
Original period of development         29 months    
Expected period of development         75 months    
Recognized revenue under agreement     800,000 5,800,000 $ 2,600,000 15,900,000  
Deferred revenue     15,200,000   15,200,000   17,700,000
Additional Potential Milestone Payments per IND filing     5,000,000   5,000,000    
License option fees received           15,000,000  
Clinical milestone payments received under agreement     0 5,000,000 0 10,000,000  
Offset to research and development costs under collaboration arrangement     0 $ 0 $ 500,000 $ 0  
Expected development period         82 months    
Review period         30 days    
Deferred revenue included in current liabilities     3,300,000   $ 3,300,000   3,300,000
Deferred revenue included in long-term liabilities     $ 11,900,000   $ 11,900,000   $ 14,400,000
Number Of Molecules To Be Developed And Commercialized Under Agreement | Molecule         3